Phase I Study of Ganetespib and Ziv-Aflibercept in Patients With Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

Trial Profile

Phase I Study of Ganetespib and Ziv-Aflibercept in Patients With Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2017

At a glance

  • Drugs Aflibercept (Primary) ; Ganetespib (Primary)
  • Indications Gastrointestinal cancer; Non-small cell lung cancer; Sarcoma; Urogenital cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Dec 2016 Results presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 26 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top